DeepMed Research

NATIONAL INSTITUTE ON DRUG ABUSE AND ADDICTION

🇵🇰Pakistan

Country: 🇵🇰Pakistan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1

Phase 2

Conditions: Health Behaviors
HIV Risk Behaviors
Adherence
Alcohol & Drug Use
Sexual Risk Behaviors

First Posted Date: 2005-09-28

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 60

Registration Number: NCT00227825

Locations: 🇺🇸
Detroit Medical Center-CHM and UHC, Detroit, Michigan, United States

Early Tobacco Abstinence - 5

Phase 1

Terminated

Conditions: Tobacco Use

First Posted Date: 2005-09-23

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 140

Registration Number: NCT00224965

Locations: 🇺🇸
Yale University, Dept. of Psychiatry, Minneapolis, Minnesota, United States

Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine

Phase 2

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: GABA Agonists

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 78

Registration Number: NCT00218166

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States

Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1

Phase 1

Completed

Conditions: Heroin Dependence

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Registration Number: NCT00218530

Locations: 🇺🇸
Substance Abuse Treatment Unit, New Haven, Connecticut, United States

Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids

Phase 2

Completed

Conditions: Opioid-Related Disorders

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 10

Registration Number: NCT00218101

Locations: 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia and Disorders With Psychotic Features
Tobacco Use Disorder
Schizophrenia

Interventions: Drug: placebo patch
Drug: Transdermal Nicotine Patch
Drug: 21 mg transdermal nicotine

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 48

Registration Number: NCT00218218

Locations: 🇺🇸
Providence VA Medical Center, Providence, Rhode Island, United States
🇺🇸
Brown University, Providence, Rhode Island, United States

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1

Phase 2

Completed

Conditions: Marijuana Abuse

Interventions: Drug: Selegiline hydrochloride
Drug: Placebo

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 19

Registration Number: NCT00218517

Locations: 🇺🇸
MRU, New Haven, Connecticut, United States

Naltrexone Augmentation of Nicotine Patch Therapy - 1

Phase 3

Completed

Conditions: Tobacco Use Disorder

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 200

Registration Number: NCT00218153

Locations: 🇺🇸
Substance Abuse Treatment Unit, New Haven, Connecticut, United States
🇺🇸
VA Connecticut Health Care System, New Haven, Connecticut, United States

Nicotine Lozenge to Reduce Smokeless Tobacco Use

Phase 2

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Nicotine Lozenge
Behavioral: Behavioral Counseling

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-10

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 100

Registration Number: NCT00218283

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens

Phase 2

Completed

Conditions: Heroin Dependence
Opioid-Related Disorders

Interventions: Drug: Levoacetyl Methadol

First Posted Date: 2005-09-22

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 142

Registration Number: NCT00218127

Locations: 🇺🇸
Department of Psychatiry, Mental Services, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy